Bartosz Hudzik/LinkedIn
May 23, 2026, 16:42
Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared his post a post on X, adding:
“HBR has become synonymous with antithrombotic de-escalation.
Yet bleeding risk alone should not determine treatment intensity.
Many AF, MI, PCI patients classified as HBR remain ischemic-risk dominant, underscoring the need for personalized rather than algorithmic therapy.”
Bartosz Hudzik shared a post on X:
“At EuroPCR 2026, we show that many HBR, AF, MI, PCI patients remain ischemic-risk dominant despite high bleeding risk.
In selected patients, triple antithrombotic therapy may still provide net clinical benefit”
Other posts featuring Bartosz Hudzik on Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow
-
May 23, 2026, 16:19Sitthiwut Chaturamaytanon: 6 Days Advancing aHUS and PNH Care in Thailand Through Collaboration